Search PubMedSearch

Biomedical subjects

P Tamburini

Publications and source records attributed to P Tamburini.

6 recordsLinked to original sources

Inhibition of cathepsin L-like cysteine proteases by cytotoxic T-lymphocyte antigen-2 beta.

The protein sequence of cytotoxic T-lymphocyte antigen-2 beta (CTLA-2 beta) is 36% identical to the proregion of mouse cathepsin L (Denizot, F., Brunet, J.F., Roustan, P., Harper, K., Suzan, M., Luciani, M. F., Mattei, M. G., and Goldstein, P. (1989) Eur. J. Immunol. 19, 631-635). Here we report the expression, purification, and characterization of recombinant murine CTLA-2 beta. The protein was purified by consecutive gel-filtration, anion-exchange, and reverse-phase (C4) chromatography. Purified CTLA-2 beta exists in solution primarily as a dimer but also as a disulfide-linked tetramer as judged by size exclusion chromatography. Circular dichroism studies suggest that the dimeric form of the protein contains 8% alpha-helix, 67% beta-sheet, and 21% random coil and also indicates that there is a conformational change upon formation of the tetramer. The protein is a competitive inhibitor of certain cysteine proteases including papain (Ki = 25 nM), cathepsins L (Ki = 24 nM) and H (IC50 = 67 nM) but not cathepsin B. CTLA-2 beta forms a noncovalent complex with cathepsin L and has a stoichiometry of binding to papain of 1 mol of CTLA-2 beta/mol of papain. There is no homology between CTLA-2 beta and any of the known cysteine protease inhibitors, including the kininogens and cystatins. Therefore, CTLA-2 beta represents a novel class of cysteine protease inhibitor that is specific for the cathepsin L family of proteases.

Antigens

[Screening studies with the BOEL test for the early diagnosis of hearing loss in infants. Experiences with 4,622 cases].

Hearing screening with reactometry in the newborn is now being considered too expensive and fails to detect quite a number of deaf children. Conversely, experiences at the age of 8 months with BOEL-Test (a distraction test, which yields further information on visual and neurological deficiencies) have shown that it becomes possible to detect the majority of hearing defects. As this age level is quite adequate for diagnosis even of defects arising in the first year (progressive genetic deafness, deafness due to infections etc.) and considering that rehabilitation can start only after this term, the authors suggest to reserve neonatal screening only for risk cases and to retest all children with the BOEL-Test.

Attention